Clinical trial • Phase I • Other
MBF-362 for Primary dysmenorrhea
Phase I trial of MBF-362 for Primary dysmenorrhea. 24 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Primary dysmenorrhea
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 16-05-2025
- First CTIS Authorization Date
- 12-08-2025
Trial design
Phase I trial across 1 site in Spain.
- Target Sample Size
- 24
Eligibility
Recruits 24 No vulnerable population selected..
- Vulnerable Population
- No vulnerable population selected.
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 18
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
Spain
- Earliest CTIS Part Ii Submission Date
- 25-07-2025
- Latest Decision Or Authorization Date
- 01-12-2025
- Processing Time Days
- 129
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau
- Department Name
- CIM
- Contact Person Name
- Rosa Mª Antonijuan
- Contact Person Email
- RantonijoanA@santpau.cat
Sponsor
Primary sponsor
- Full Name
- Medibiofarma S.L.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- MBF-362
Related trials
Other published trials that may interest you.